Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Background: Afatinib (BIBW-2992) has been approved for patients with untreated metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations. The aim of our study is to identify the correlation between DNA copy number profiles and treatment response to Afatinib.Methods: Integrative analysis of DNA copy number alterations (CNA) from 32 metastatic NSCLC patients were performed to identify recurrent regions of genomic change associated with primary response to Afatinib using Affymetrix Mapping 250K Nsp SNP array. Copy number-associated transciptome profiling was identified using Affymetrix Human genome U133 Plus 2.0 array. Comparison of candidate genes correlated with copy number variation and clinical outcome of Afatinib treatment was conducted by quantitative-PCR (qPCR).Results: Predictive model scores generated from cross-validation was correlated with sensitivity to Afatinib. Eight distinct genomic regions were identified in predictive model for Afatinib sensitivity. Regions contained chromosomal gain of EGFR (7p11.2) as well as chromosomal loss of HSD3B2 (1p12) and MTAP (9p21.3). The extreme concordance between DNA copy number and transcript abundance was highly significant for the genes mapping to 7p11.2 in Afatinib sensitive group. Specially, amplification of CCT6A was related to the intrinsic resistance to Afatinib.Conclusions: These data show that integrative analysis of DNA copy number analysis can be used to identify genetic alterations which can be used to discover clinically relevant predictors of drug sensitivity to Afatinib.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Xie, S. H. Wei, M. He (Guangzhou, Beijing, Shanghai, China). Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib. Eur Respir J 2014; 44: Suppl. 58, 507

Member's Comments

No comment yet.

Related content which might interest you: The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC) Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 The prognostic value of KRAS mutation according to the gene's Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Functional impairment of NK cells in non-small-cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014